Results 151 to 160 of about 23,127 (334)
Obesity Reviews, EarlyView.ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira +8 more
wiley +1 more source
Amino acids, glucose metabolism and clinical relevance for phenylketonuria management [PDF]
, 2015 It is general knowledge that glycaemia is affected by digested nutrients.Amino acids intake appears to be an important regulator in this regard. Many questions need to be answered, such as the real mediators of this responseand the mechanisms underlying ...
Borges, Nuno, Pena, MJ, Rocha, JC
core
Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
Obesity Reviews, EarlyView.ABSTRACT Introduction Increased risk of suicidality has been reported in association with glucagon‐like peptide receptor agonist (GLP‐1 RA) prescription. Herein, we conducted a comprehensive review evaluating reports of GLP‐1 RA prescription and suicidality.
Hezekiah C. T. Au +9 more
wiley +1 more source
Obesity Reviews, EarlyView.ABSTRACT Background/Aim We conducted a systematic review with network meta‐analyses (NMA) summarizing the effects and safety of lifestyle interventions containing nutrition (NUT; e.g., calorie restriction), exercise (EX; e.g., aerobic/resistance exercise) and behavior change interventions (BCI; e.g., behavioral therapy) on physical function, body ...
Gabriel Torbahn +12 more
wiley +1 more source
The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
PharmaceuticalsTraumatic brain injury (TBI), which is a global public health concern, can take various forms, from mild concussions to blast injuries, and each damage type has a particular mechanism of progression.
Anja Harej Hrkać +5 more
doaj +1 more source
The GLP‐1 Receptor Agonist Paradox in Dermatology: Why We Cannot Afford the Knowledge Gap
International Journal of Dermatology, EarlyView.
Ramy Awadalla, Derek Davies
wiley +1 more source
Low Weight Loss Response to Incretin Analogs: A Systematic Review
Obesity Reviews, EarlyView.ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley +1 more source
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
Obesity Reviews, EarlyView.ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani +8 more
wiley +1 more source
c‐Jun N‐terminal kinase 3 as a permissive regulator of β‐cell incretin responsiveness
Journal of Diabetes Investigation, EarlyView.
Yuji Yamazaki
wiley +1 more source
Experimental Physiology, EarlyView.Abstract Sitting‐induced impairments in postprandial blood flow are an important link between sedentary behaviour and cardiometabolic disease risk. The objective of this work was to examine the effects of resistance exercise breaks (REB) performed every 30 min during an otherwise sedentary 3‐h period on the vasodilatory response to a subsequent oral ...
Emily M. Rogers +8 more
wiley +1 more source